Supriya Lifescience eyes strong growth in Latin America with 10 newly registered APIs

Mumbai-based Supriya Lifescience, a global leader in the production of Active Pharmaceutical Ingredients (APIs), is eyeing significant expansion in the Latin American market. The company's successful registration of 10 APIs marks a key milestone, paving the way for an expected incremental revenue of ₹300 crore.

In an interview with CNBC-TV18, Satish Wagh, the Chairman and Managing Director (CMD) of Supriya Lifescience, highlighted that the achievement follows the certification of their manufacturing site in Maharashtra with good manufacturing practice approval from the Brazilian regulatory authority.

"We have already registered 10 APIs out of 15. I am hopeful that within the next two years, we will attain at least ₹300 crore more in the Latin American market, especially in Brazil," expressed Wagh.

| Pharmaceutical industry in 2024 — Key trends, top picks, and future projections

Discussing the company's margin guidance, Wagh said, "We aim to double our margins within the next four years, and our EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) will continue to grow."

Also Read | India tightens rules to enforce stricter good manufacturing practices at pharma units

The API manufacturer has a market capitalisation of ₹2,472.83 crore.

For the entire interview, watch the accompanying video